Alzheimer’s Disease
Alzheimer’s Disease
At INmuneBio, we view Alzheimer’s as an immunologic disease with the neurological symptoms of dementia.
Approaching Alzheimer’s disease as an immunologic disease changes the drug discovery process, changes the way clinical trials are designed, and may provide hope for patients and their care-givers.
We are currently enrolling a phase 2 study to determine whether XPro1595 can slow Alzheimer’s disease.
The MINDFuL study is a Phase 2 study investigating the effectiveness of XPro1595 in early Alzheimer’s disease patients with biomarkers of inflammation.
Click HERE to learn more
Cancer
Cancer
The most clinically effective treatments for cancer are focused on targeting and activating NK cells. Activation of NK Cells is required to kill cancer cells.
Activation of NK cells requires multiple signals, which typically come from the cancer cell and result in cell-to-cell contact. Once connected, activated NK cells lyse (kill) tumor cells.
In certain cancers, and in cancer relapse, the NK Cells are not activated. INKmune is an innovative biologic delivery system that primes the patients own resting NK Cells to target and kill cancer cells.
We are currently evaluating INKmune in two clinical trials:
The LAUREL study is a Phase l/lla trial in patients with relapsed MDS or AML post-allogeneic stem cell transplant. Click HERE to learn more
The CaRe Prostate study is a Phase l/ll trial in patients with metastatic Castrate resistant prostate cancer.Click HERE to learn more
